Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy
ConclusionsMYD88L265P mutation and underlying haemopathies are not predictive of a more severe disease. However, in cases of resistant and progressive neuropathy, they provide an opportunity to prescribe newly available drugs such as Bruton tyrosine kinase inhibitors.
Source: Journal of Neurology - Category: Neurology Source Type: research
More News: Ataxia | Bone Marrow Aspiration and Biopsy | Brain | Cancer & Oncology | Disability | Genetics | Lymphoma | Macroglobulinemia | Neurology | Rituxan | Waldenstrom's Macroglobulinemia